Kaiser Permanente denied your biologic and infusion therapy? Here is what to do next

Why Kaiser Permanente denies biologic and infusion therapy

Kaiser Permanente is a vertically integrated system, the insurer (Kaiser Foundation Health Plan), medical groups, and hospitals operate as one closed network. Because the treating physician and the plan share an employer, the appeal pathway looks different from a typical PPO denial: the dispute is often with the in-house utilization-review decision rather than with a separate carrier.

For biologic and infusion therapy specifically: Biologics such as adalimumab, infliximab, vedolizumab, ustekinumab, and rituximab are denied at prior authorization for step-therapy, missing labs, or diagnosis mismatch, and later for site of care or dose escalation. The appeal is a documentation exercise against the plan's own criteria.

What Kaiser Permanente denies for biologic and infusion therapy

The biologic and infusion therapy services most often denied:

• First biologic for Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, or psoriasis
• Switch to a second biologic after the first stops working
• Dose escalation or interval shortening beyond the label
• Infusion at a hospital outpatient department instead of home or a standalone center
• Biosimilar substitution disputes

Why biologic and infusion therapy claims get denied

A typical Kaiser Permanente biologic and infusion therapy denial almost always cites one of these reasons. Each one maps to a specific rebuttal in the appeal:

• Step therapy: conventional drugs (methotrexate, mesalamine, steroids) not tried or not documented
• Disease activity scores or lab markers missing from the record
• Diagnosis code does not match the labeled indication
• TB or hepatitis B screening not on file
• Plan prefers a different biologic or a biosimilar first

The Kaiser Permanente appeal process

Appeal levels: Internal grievance / appeal, then state external review (e.g. DMHC IMR in California). Medicare Advantage follows the federal 5-level ladder: plan → IRE (MAXIMUS) → ALJ → Council → federal court.

Carrier timing: 180 days from denial for internal appeal in most commercial plans; 60 days between each level for Medicare Advantage. Expedited urgent decisions within 72 hours.

Biologics timing: Untreated inflammatory disease supports an expedited appeal: decision within 72 hours. Internal appeal filing window: at least 180 days for commercial and employer plans; 65 days for Medicare Advantage; 60 days for Part D. External review: within 4 months of the final internal denial for ACA-covered plans (45 CFR 147.136).

What we know about Kaiser Permanente: We coordinate Kaiser appeals through the member-services grievance system while preserving the IMR / external-review pathway. Documenting the closed-network constraint is often the unlock on out-of-plan-referral cases.

Common Kaiser Permanente denial patterns for biologic and infusion therapy

• Internal grievance before external review. Kaiser members file a grievance with Member Services first. In California, Kaiser's largest market, DMHC oversight applies, and the IMR (Independent Medical Review) pathway opens after Kaiser's final internal decision. Members in other states route to their state DOI or to an IRO.
• Out-of-network referral denials. Because Kaiser is closed-network, most non-emergent out-of-plan care must be authorized in advance. Denials are common when a member seeks a specialist outside the system; the strongest appeal lane is a clinical-necessity argument that the in-network alternative is unavailable or inadequate.
• Medicare Advantage escalates to MAXIMUS. Kaiser's Senior Advantage plans follow the federal 5-level Medicare Advantage ladder. After Kaiser's plan-level reconsideration, the case goes to MAXIMUS Federal Services (the IRE), an external escalation that frequently reverses plan denials when the clinical record is complete.

How to win your Kaiser Permanente biologic and infusion therapy appeal

Strategy for biologic and infusion therapy: Get the plan's drug policy and match every criterion to a page in the chart: diagnosis, severity score, prior drugs with dates and outcomes, screening labs, prescriber specialty. Where step therapy is the reason, use the plan's exception process and, where applicable, the state step-therapy law that requires an override when the required drug was tried, is contraindicated, or is expected to be ineffective. For a switch after loss of response, document the objective loss of response. Ask for a peer-to-peer with a reviewer in the same specialty.

Filed against Kaiser Permanente, that strategy rides on this procedural spine:

1. Procedural-rights anchor. Every Kaiser Permanente denial triggers ERISA § 503 or 45 C.F.R. § 147.136 procedural rights. The cover letter invokes these in the opening paragraph to lock the timeline and force criteria disclosure.
2. Criteria-disclosure demand. Kaiser Permanente frequently denies on "not medically necessary" without disclosing the clinical criteria applied. Once disclosed, those criteria become the rebuttal map.
3. Controlling-standard citation. Plan drug policies typically require a specific diagnosis, disease severity measures, a trial of conventional therapy (step therapy), tuberculosis and hepatitis screening, and prescriber specialty. Many states limit step therapy and require exception processes; federal rules for ACA plans require an exceptions process for non-formulary drugs (45 CFR 156.122(c)). Medicare Part B covers physician-administered biologics under medical necessity; Part D covers self-administered ones under formulary rules with a 60-day redetermination window (42 CFR 423.582). Criteria must be disclosed on request (29 CFR 2560.503-1(m)(8)).
4. Treating-provider attestation. A letter from the treating physician addressing each criterion in Kaiser Permanente's own policy language. This is the single strongest evidentiary element.
5. Requested action. A specific demand to reverse the biologic and infusion therapy denial and approve the service, not a general "please reconsider."

Documents you'll need for your Kaiser Permanente biologic and infusion therapy appeal

• The denial letter with the criterion or policy cited
• Specialist's notes with diagnosis and disease-activity measures
• Prior medication history with dates, doses, and outcomes
• TB, hepatitis, and other screening results
• The plan's drug policy and formulary exception form

What a biologic and infusion therapy appeal can recover

Typical recovery for biologic and infusion therapy cases runs Biologics are priced in the thousands of dollars per dose; a denied year of therapy is commonly a five-figure sum at billed charges.. The exact figure depends on the specific service and your plan's contracted rates.

Kaiser Permanente biologic and infusion therapy appeals: frequently asked questions

What Apellica does for Kaiser Permanente biologic and infusion therapy appeals

We file appeals against Kaiser Permanente specifically configured to its internal review process. Every biologic and infusion therapy appeal embeds the criteria-disclosure demand, the procedural-rights anchor, the controlling-standard citation above, treating-provider attestation language, and the peer-reviewed evidence relevant to the denied service.

Cost: $0 upfront. We work on contingency for Kaiser Permanente appeals, if the appeal succeeds, we collect a percentage of the recovered claim value. If it fails, you owe nothing.

Related Kaiser Permanente guides

• Kaiser Permanente surgery denials appeal guide
• Kaiser Permanente mri and imaging denials appeal guide
• Kaiser Permanente medication and prescription denials appeal guide
• Kaiser Permanente medicare denials appeal guide

Biologic and infusion therapy guides for other carriers

• UnitedHealthcare biologic and infusion therapy appeal guide
• Aetna (CVS Health) biologic and infusion therapy appeal guide
• Cigna (Evernorth) biologic and infusion therapy appeal guide
• Anthem / BlueCross BlueShield biologic and infusion therapy appeal guide